Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

NCT03850418 is registered in ClinicalTrials.gov with Henry Ford Health System as lead sponsor.

NCT NCT03850418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03850418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Lead sponsor
Henry Ford Health System
Phase
Phase 2
Overall status
Recruiting
Start date
July 1, 2019
Completion date
February 20, 2028
Enrollment
43 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid malignancy